
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

June 9, 2015
Date of Report (Date of earliest event reported)

BOVIE MEDICAL CORPORATION

(Exact name of registrant as specified in its Charter)

Delaware
(State or other jurisdiction of
incorporation)

012183
(Commission File Number)

11-2644611
(IRS Employer Identification No.)

4 Manhattanville Road, Suite 106
Purchase, New York 10577
(Address of principal executive offices) (Zip Code)

(914) 468-4009
Registrant's telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Peter L. Donato, Chief Financial Officer and Secretary of Bovie Medical Corporation (the “Company”), notified the Company on June 9, 2015, that he intends to resign from his service as Chief Financial Officer, Executive Vice President, Treasurer and Secretary of the Company on or about June 25, 2015.

On June 15, 2015, the Board of Directors of the Company (the “Board”) appointed Jay Ewers, currently the Controller of the Company, as the Interim Chief Financial Officer, Treasurer and Secretary of the Company effective upon Mr. Donato’s resignation.

Mr. Ewers, age 54, has more than 30 years of senior experience and has held financial executive positions in corporations ranging from early stage to high profile public companies with global operations in the medical equipment, manufacturing and semiconductor industries. From June 2014 to the present, he has served as Corporate Controller of the Company. Prior to that, from January 2004 until June 2014, he was the principle and founder of Ewers Group providing compliance and internal audit services to Fortune 1000 companies. He has extensive experience with Sarbanes Oxley, inventory management, Oracle modules and financial planning & analysis. Mr. Ewers is a certified public accountant, internal auditor, and holds a BS in Accounting.

The compensation that Mr. Ewers will receive in his role as Interim Chief Financial Officer, Treasurer and Secretary has not yet been determined by the Compensation Committee of the Board (the “Committee”), and an amendment to this Current Report on Form 8-K will be filed at a later date to disclose such compensation when a determination has been made. There are no arrangements or understandings between Mr. Ewers and any other person pursuant to which he was selected as an officer. Mr. Ewers does not have any family relationship with any director or other executive officer of the Company or any person nominated or chosen by the Company to become a director or executive officer, and there are no transactions in which Mr. Ewers has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits

(d)

Exhibit No.	Description
99.1	Press release dated June 15, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BOVIE MEDICAL CORPORATION

Date: June 15, 2015

By: /s/ Robert Gershon
Robert Gershon
Chief Executive Officer

BOVIE MEDICAL CORPORATION ANNOUNCES CFO TRANSITION**– Jay Ewers Appointed Interim CFO –**

CLEARWATER, FL — June 15, 2015 –Bovie Medical Corporation (“Bovie” or the “Company”) (NYSE: BVX), a maker of medical devices and supplies, and the developer of J-Plasma®, a patented new surgical product, today announced that Peter Donato, Chief Financial Officer, will leave the company on or about June 25, 2015 to take a position in his home state of Ohio.

Jay Ewers, Corporate Controller, has been appointed interim CFO effective upon Mr. Donato's departure. Mr. Ewers has more than 30 years of senior experience and has held financial executive positions in corporations ranging from early stage to high profile public companies with global operations in the medical equipment, manufacturing and semiconductor industries. He has extensive experience with Sarbanes Oxley, inventory management, Oracle modules and financial planning & analysis. Mr. Ewers is a certified public accountant, internal auditor, and holds a BS in Accounting.

Bovie Medical will engage an executive search firm to conduct a search for a permanent CFO.

“We appreciate Peter’s contribution during the time he has been with us and wish him the best,” said Robert L. Gershon, Chief Executive Officer. “We are fortunate to have a senior executive with Jay’s experience and a supporting financial team. Jay has played a key role in managing finance-related functions at Bovie Medical.” Mr. Donato has entered into a consulting agreement to assist Mr. Ewers’ seamless transition to interim CFO until a permanent CFO is named.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website www.boviemed.com

Cautionary Statement on Forward-Looking Statements

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company's filings with the Securities and Exchange Commission including the Company's Report on Forms 10-Q for the quarter ended March 31, 2015 and 10-K for the year ended December 31, 2014. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations Contact

Hugh Collins /Jane Searle
MBS Value Partners
(212) 750-5800
investor.relations@boviemed.com